Evalon

There is no image.

Estradiol

Method of action: Endocrine Therapy, Estrogenic, Replenishment Of Estrogen Deficiency, Sex Hormones And Modulators Of The Genital System

Treatment option: Atrophic urethritis, Vaginal Atrophy, Hypogonadism, Hypoestrogenism, Menopause And Perimenopause, Osteoporosis, Primary Ovarian Failure

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Evalon

Evalon is a pharmaceutical preparation utilized for Hormone Replacement Therapy (HRT), primarily addressing local symptoms related to estrogen deficiency in postmenopausal women.

Property	Description
Active ingredient	Estriol (INN: Oestriol)
Form	Vaginal Cream, Tablet, Vaginal Suppository
Pharmacological class	Estrogen (Steroid Hormone Derivative)
Common use	Hormone substitution for urogenital symptoms
Origin	Bio-identical or Semisynthetic

What Type of Medicine is Evalon?

Evalon is formally classified as an Estrogen, a type of steroid hormone that belongs to the Gynaecological therapeutic class. The active compound, Estriol (Oestriol), is structurally identical to an estrogen naturally produced by the human body, classifying it as bio-identical. This characteristic means the body interacts with the compound precisely as it would with its own natural hormone.

This medication is distinct from other estrogen therapies because Estriol is recognized as a relatively weak and short-acting estrogen, a property clinically supported by numerous pharmacological studies. This distinction in potency makes it well-suited for targeted treatment, such as relieving the chronic dryness and irritation experienced by some postmenopausal women.

Composition and Physical Forms

The composition of Evalon centers entirely on the active ingredient Estriol and is typically a single active ingredient product. Estriol is formulated into various dosage forms, including the most common Vaginal Cream and Tablet forms.

The form dictates the route of administration: the cream is applied intravaginally (topically), while the tablets are administered orally. The intravaginal preparations are favored for their design to ensure low systemic bioavailability, maximizing the localized support needed for the target tissues.

The Fundamental Action of Estriol

The action of Evalon is based on the principle of replenishing the body's deficient estrogen supply in localized tissues. The Estriol acts by engaging specific estrogen receptors, providing the necessary hormonal signal to the urogenital cells.

This action stimulates the normalization of the urogenital epithelium, a key physiological outcome consistently reported in clinical literature. This restoration process is the underlying mechanism that delivers the general therapeutic benefit of relieving localized physical symptoms related to tissue fragility and dryness.

What side effects are possible with Evalon?

The safety profile for Evalon (Estriol) is formally categorized into anticipated local effects and the systemic risks associated with the general Estrogen drug class, as documented by regulatory bodies such as the European Medicines Agency (EMA).

Adverse Reaction Scope

The adverse reactions documented in the regulatory labeling are primarily grouped by frequency and the body system affected.

Classification	Examples of Reactions (Based on SmPC/Label)
Common	Vaginal discomfort, irritation, or itching, especially at the start of treatment; breast tenderness or pain; headache; nausea.
System-Organ Classes	Reproductive System and Breast Disorders (e.g., vaginal discharge, spotting); Nervous System Disorders; Gastrointestinal Disorders; General Disorders (e.g., flu-like symptoms).

Serious Adverse Reactions (Systemic HRT Class Effects)

As an estrogen, Estriol's official label must document the potential for serious risks associated with systemic Hormone Replacement Therapy (HRT), even though local use typically results in lower systemic exposure. These mandated warnings include the risk of Venous Thromboembolism (VTE) (blood clots), Stroke, Endometrial Hyperplasia/Cancer (in women with an intact uterus), and Breast Cancer.

Population-Specific Constraints

The official documentation includes specific safety notes for certain populations:

Women with an Intact Uterus: Unopposed Estrogen (Estriol alone) is associated with an increased regulatory risk of endometrial hyperplasia and cancer, as stated in the product information.
Time-Related Pattern: Local irritation and itching are often stated to be more pronounced during the initial weeks of use, typically resolving as treatment continues.

Regulatory Safety Restrictions

Co-Administration: The medicine's use is officially restricted or discouraged in women concurrently taking other systemic HRT medicines.
High-Strength Forms: Certain regulatory authorities require that high-strength intravaginal products be limited to a maximum single treatment period (e.g., four weeks) due to concerns regarding systemic absorption.

Overdose and Emergency Response

Evalon Overdose and When to Seek Help

The official regulatory profile for Evalon (Estriol) overdose addresses the risks associated with excessive exposure, primarily the circumstance of accidental oral ingestion of the vaginal cream or pessary. The documented clinical signs of over-exposure are typically limited to the drug’s known adverse reactions, which are officially classified as generally transient and reversible upon dose reduction or cessation. Following a large oral ingestion, expected symptomatic manifestations may include gastrointestinal disturbances such as nausea and vomiting. Furthermore, withdrawal bleeding is a known estrogenic effect that may occur in overdose scenarios.

Exposure Context	Mandated Action
Accidental Oral Ingestion	Contact a doctor immediately or visit the nearest hospital.
Topical Over-application	Wipe out the excess medicine with tissue or cotton.

Management of an overdose is symptomatic and supportive. For severe cases involving significant oral ingestion, official labeling states that an appropriate method of gastric emptying may be considered by healthcare professionals. It is specifically noted that no specific antidote is known for Estriol overdose. The requirement to seek immediate medical attention is strictly mandated by regulatory authorities following the event of accidental oral ingestion of the product.

Therapeutic Uses of Evalon

Evalon: Main Uses and Benefits

Evalon is commonly used for managing Genitourinary Syndrome of Menopause (GSM), in conditions involving localized symptoms. It may offer supportive relief across several symptom clusters, including vaginal dryness, burning, irritation, dyspareunia (painful intercourse), and associated urinary urgency and frequency. This supportive approach is relevant in clinical settings marked by the heightened distress of chronic tissue thinning due to estrogen deficiency.

The medication is often applied during phases of increased discomfort or tension, such as long-term supportive care for persistent symptoms. It is commonly used in scenarios involving gynecological surgery, where additional management of discomfort is required. It helps address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load and assisting with maintaining functional stability. It is considered relevant in managing the localized consequences of menopause.

Quick Fact: Relevant Symptom Context
Primary Domain: Genitourinary Syndrome of Menopause (GSM).
Key Benefit: Supports general well-being and sexual comfort.
Associated Use: May assist in easing the symptomatic burden of recurrent urinary tract irritations (RUTI).
Typical Context: Used for long-term chronic management.

Regulatory References

National Institutes of Health (NIH) research on vaginal estriol

Eligibility and Restrictions for Use

Who Can and Cannot Use Evalon?

Evalon is intended for use in postmenopausal women to address local symptoms of estrogen deficiency. Eligibility for the medicine is strictly defined by regulatory authorities based on specific medical history and physiological status.

Classification	Status as Defined in Regulatory Labels
Eligible Population	Postmenopausal women only
Pediatric Use	Use is not indicated for children or adolescents

Absolute Contraindications (Must Not Use)

Evalon is contraindicated and must not be used by individuals with a history of or current breast cancer or other estrogen-dependent malignant tumors. Use is also prohibited if there is undiagnosed genital bleeding, untreated endometrial hyperplasia, or a history of Venous Thromboembolism (VTE), thrombophilic disorders, or active arterial thromboembolic disease (e.g., heart attack, stroke). The medicine is also contraindicated in acute liver disease and during pregnancy or lactation.

Conditional Use (Requires Close Supervision)

Special consideration and close supervision are required if the patient has conditions such as hypertension, diabetes mellitus, uterine fibroids (leiomyoma), endometriosis, Systemic Lupus Erythematosus (SLE), or cardiac/renal dysfunction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Evalon’s official interaction profile is structured around the established metabolism of the estrogen class, focusing on substances that modify its systemic plasma concentration. The most common documented interactions are pharmacokinetic, primarily mediated through the Cytochrome P450 3A4 (CYP3A4) enzyme system.

Metabolic Pathway Interactions

Co-administration with CYP3A4 inducers may reduce Estriol plasma concentrations, potentially resulting in decreased systemic exposure. Officially listed inducers include Rifampin, Phenobarbital, and Carbamazepine. Conversely, inhibitors of the CYP3A4 enzyme may increase Estriol plasma concentrations, resulting in increased systemic exposure. Documented inhibitors include antifungal agents like Ketoconazole and certain antibiotics such as Erythromycin.

Food, Herbal, and Testing Constraints

Specific non-medicinal substances also alter Estriol exposure. The herbal product St. John’s Wort is officially listed as a CYP3A4 inducer that reduces exposure, while Grapefruit juice is documented as a CYP3A4 inhibitor that increases exposure. Furthermore, a pharmacodynamic restriction is noted with thyroid hormone replacement therapy. Estriol may interfere with Thyroid-Binding Globulin measurement, necessitating the monitoring of thyroid function tests in individuals taking these hormones. No specific drug-drug combinations are formally labeled as contraindicated based on interaction risk.

Mechanism of Action

The mechanism of action for Evalon is strictly localized, centered on the pharmacodynamic properties of its single active ingredient, Estriol (Oestriol). Its action involves agonist binding to Estrogen Receptors, resulting in the modulation of the tissue's cellular architecture.

Nuclear Receptor Agonism and Gene Activation

The mechanism initiates when Estriol functions as an agonist, directly binding to and activating the intracellular Estrogen Receptors ( ERalpha and ERbeta) within target cells. This interaction forms a complex that translocates to the cell nucleus, where it modulates gene transcription, which is the foundational molecular step shaping cellular processes. This activity defines Estriol as a weak and short-acting estrogen, influencing tissues where local concentration is maximized.

Epithelial Maturation and Proliferation

The molecular signal initiates a crucial mechanistic cascade involving cell growth and differentiation. Estriol-mediated gene expression stimulates the proliferation and maturation of the urogenital epithelium, promoting the multi-layered tissue architecture and influencing local blood flow and connective tissue element production. This structural remodeling process results in the development of a thicker, more stable tissue architecture.

Influence on Local Microenvironment via Glycogen Synthesis

A physiological consequence includes the promotion of glycogen synthesis and storage within the mature epithelial cells. This mechanism operates as the breakdown of accumulated glycogen by local flora facilitates the production of lactic acid, which establishes the acidic microenvironment. This action is integral to the mechanism that dictates the final tissue state.

Dosage and Administration Information

How to Use Evalon

Evalon, which contains the active ingredient Estriol, is officially administered via the intravaginal route, primarily in the form of a cream or suppository. The usage protocol is structured as a two-phase regimen that ensures the correct dose is delivered and the duration of use is organized.

Administration and Dosing Schedule

The standard dose unit is 0.5 mg of estriol. This is measured using a calibrated applicator supplied with the cream, which must be filled only up to the specified mark to ensure accurate dosing.

Usage Phase	Dose	Frequency and Duration
Initial Course	0.5 mg (one applicator dose)	Once daily for a period of 2 to 4 weeks
Maintenance	0.5 mg (one applicator dose)	Reduced to twice a week for long-term management

Procedural Rules and Timing

Following the initial daily course, the treatment frequency must be reduced to the twice-weekly maintenance schedule. This structural pattern is designed to transition from early tissue saturation to a long-term, intermittent routine. The treatment plan includes specific procedural rules related to surgical contexts.

For patients undergoing gynecological surgery, the medication is applied once daily for 2 weeks prior to the operation. Use must then be suspended for at least 2 weeks following surgery, after which the twice-weekly maintenance dose may begin.

If an application is missed, it should be applied as soon as the user remembers, unless the delay exceeds 12 hours, in which case the missed dose must be skipped.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early Phase Research

Initial studies in healthy participants and individuals with X-Syndrome were conducted to explore appropriate exposure levels and assess basic safety parameters. This research provided data used to determine dose ranges for later-stage trials.

Pharmacokinetics: Studies were conducted to determine how the body absorbs, distributes, and eliminates the drug.
Relationship with Biological Markers: Research has examined the relationship between the drug and cellular pathways thought to be involved in the progression of X-Syndrome.

Clinical Efficacy Trials

Clinical trials have primarily focused on two main areas: the use of the study drug as a monotherapy and its use in combination with existing standard treatments.

Monotherapy Studies

Research has evaluated whether the study drug may affect certain symptoms of X-Syndrome. A multi-center Phase 3 trial included participants with moderate forms of the condition.

Outcome Type	Measures Evaluated	Key Findings from Studies
Primary	Measured outcomes in pain levels (VAS) and quality of life metrics.	Studies explored outcomes in participants with mild-to-moderate forms of the condition.
Secondary	Changes in the frequency of episodes; need for rescue medication.	Findings regarding incidence and intensity of flare-ups varied across studies.

Combination Therapy Studies

Research also investigated the study drug's use alongside Drug Z, a currently approved treatment. These studies compared the outcomes of participants receiving the investigational drug plus Drug Z versus those receiving Drug Z plus a placebo.

Observed Measures: The combination regimen examined effects on the duration and intensity of flare-ups. In one study, the combination was associated with a decrease in disease severity, as measured by the Disease Activity Index.

Safety and Tolerability

The overall research program includes data from over 2,000 participants across various trial phases.

Reported Events: Observations included commonly reported events such as mild headache, gastrointestinal discomfort, and temporary localized irritation at the injection site.
Long-term Monitoring: Ongoing, open-label extension studies are continuing to gather data on the extended safety profile of the drug.
Drug-Drug Interactions: Research has investigated the interaction of this drug with anticoagulants. Safety and tolerability were assessed in adult participant groups. Further research is planned to better understand potential interactions.

Frequently Asked Questions (FAQ)

Common questions about Evalon (FAQ)

Q: What is Evalon used for besides the main indication?

A: Official product information indicates that in addition to treating local symptoms of estrogen deficiency, Evalon is also used to support the condition of the vaginal area before and after vaginal surgery in postmenopausal women.

Q: How quickly should I expect to see results after starting Evalon?

A: Regulatory guidance suggests that localized symptoms, such as irritation and itching, may begin to improve after a few weeks of starting treatment. This timeline aligns with the duration of the initial daily use phase.

Q: Is Evalon safe for long-term use?

A: When using any estrogen therapy, including locally applied treatment like Evalon, regulatory agencies recommend using the lowest effective dose for the shortest possible duration consistent with treatment goals. The need for continued long-term use is typically reviewed regularly by a healthcare professional.

Q: Can Evalon cause weight gain or loss?

A: Weight changes are not listed as a frequently reported side effect in the official product information for Evalon. Weight increase is not generally listed as a common or very common side effect.

Q: Do you have to use Evalon every day?

A: Official product labeling specifies that Evalon usage involves two phases. The initial daily use phase is typically for a period of two to four weeks. After this period, the frequency is reduced to the maintenance schedule, which is often twice a week.

Q: Can Evalon be used by men?

A: The official indication for Evalon is strictly for the treatment of local estrogen deficiency symptoms in postmenopausal women. The product is not indicated or recommended for use by men.

Q: Is a slight burning sensation normal when starting Evalon?

A: Regulatory documents list vaginal irritation, discomfort, or itching as a common side effect, especially at the start of treatment. This localized irritation typically starts to lessen or resolve after the first few weeks of consistent use.

Q: Does Evalon interfere with birth control pills?

A: Regulatory documents note that the metabolism of estrogens can be increased when taken with certain enzyme-inducing substances. It is always important to discuss all medicines, including hormonal contraceptives, with a healthcare professional to identify potential interactions.

Q: Is Evalon a steroid?

A: Evalon contains the active substance Estriol, which is classified as an estrogen hormone. Estrogens are a type of steroid hormone naturally produced by the body.

Q: Is it normal to have some vaginal discharge when using Evalon?

A: Official adverse reaction reports indicate that increased vaginal discharge is a known side effect that may occur while using the medicine. This is a common observation associated with the use of the product.

Q: Can Evalon be used if I have sensitive skin?

A: Official information states that the medicine is contraindicated if a person is allergic to any of the ingredients. Individuals with a history of sensitive skin or allergies should consult their healthcare provider before use.

Q: Can I drink alcohol while I'm using Evalon?

A: There are no specific warnings or formal contraindications listed for alcohol consumption in the official product labeling for Evalon.

Q: Is there any research on Evalon's impact on bone density?

A: As Evalon contains an estrogen, research has explored the effect of the active ingredient, Estriol, on bone mineral density and the prevention of osteoporosis.

Q: Can I use Evalon if I have allergies to certain ingredients?

A: Evalon is contraindicated (should not be used) if a person is allergic to the active substance, Estriol, or to any of the other ingredients listed in the product leaflet, as stated in regulatory documents.

Q: Why is consistency important when using Evalon?

A: Following the prescribed dosing schedule consistently is important to help achieve and sustain the localized therapeutic effects of the hormone on the vaginal tissues.

Q: Does Evalon require special monitoring or blood tests?

A: Regular medical check-ups are typically advised while using the medicine, in alignment with official guidance. These checks may include routine monitoring like breast and cervical screening, and blood pressure measurement.

Q: Is Evalon considered safe for women over 65?

A: For all hormone replacement therapies, official warnings note that starting treatment over the age of 65 years has been associated with an increased risk of probable dementia. The decision to use this medication for those over 65 involves a careful consideration of the localized benefits versus the potential systemic risks.

Q: Is Evalon effective for urinary symptoms?

A: Regulatory documents indicate that Evalon is used to treat urogenital symptoms related to estrogen deficiency. These may include miction complaints (urinary symptoms) and mild urinary incontinence.

Q: Can Evalon make symptoms worse before they get better?

A: Official information notes that local side effects, such as irritation or itching, may be more pronounced when you first start using the medicine. These local effects, however, usually lessen and improve after a few weeks.

Q: What should I do if Evalon gets into my eyes?

A: Regulatory guidance states that if the product accidentally gets into the eyes, they should be rinsed thoroughly with clean water immediately.

Q: Are there any food interactions with Evalon?

A: Regulatory information documents that certain non-medicinal substances, such as the herbal product St. John’s Wort and grapefruit juice, are known to interact with the metabolism of the estrogen component of Evalon.

Q: Can Evalon be used by premenopausal women for specific conditions?

A: The official indication for Evalon is strictly limited to treating local symptoms of estrogen deficiency in postmenopausal women. It is not indicated for use in premenopausal women.

Q: Why might a doctor switch a patient from oral HRT to Evalon?

A: Official documentation highlights that local vaginal treatments like Evalon result in significantly lower absorption of the hormone into the systemic bloodstream. The lower systemic exposure of Evalon means it may be used when a reduced risk of systemic effects, such as those associated with oral hormone replacement therapy, is desired.

How should Evalon be stored and disposed of?

Evalon Cream must be stored in specific conditions to maintain its effectiveness and stability, as defined by regulatory labeling. The product must be stored below 25 C and must not be frozen. It should be kept in its original container and stored in a dry place away from excess heat and direct sunlight.

Handling and Safety	Disposal Requirements
Mandatory to keep out of the sight and reach of children and pets.	Discard unused or expired cream according to local regulations.
Stability is guaranteed until the printed expiry date, provided conditions are met.	Do not dispose of the medication via wastewater or household waste unless instructed.